NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis → The Small Biotech with a BIG Cancer Solution (From Behind the Markets) (Ad) Free ABCL Stock Alerts $4.57 +0.08 (+1.78%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$4.51▼$4.6250-Day Range$4.29▼$5.5952-Week Range$3.87▼$8.05Volume79,217 shsAverage Volume1.43 million shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$15.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AbCellera Biologics alerts: Email Address AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside253.2% Upside$15.86 Price TargetShort InterestBearish11.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.64) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector665th out of 939 stocksPharmaceutical Preparations Industry310th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.86, AbCellera Biologics has a forecasted upside of 253.2% from its current price of $4.49.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.23% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 1.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 3.4 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AbCellera Biologics this week, compared to 2 articles on an average week.Search Interest34 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.MarketBeat FollowsOnly 17 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.64) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesMarch 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 StocksMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | businesswire.comAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024March 11, 2024 | msn.comAbCellera gains on antibody collaboration with BiogenMarch 5, 2024 | businesswire.comAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024February 29, 2024 | finance.yahoo.comAfter losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gainFebruary 28, 2024 | seekingalpha.comAbCellera: Victim Of Its Own SuccessMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 23, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)February 23, 2024 | businesswire.comAbCellera Announces Resignation of Board MemberFebruary 23, 2024 | finance.yahoo.comABCL Mar 2024 4.000 callFebruary 23, 2024 | finance.yahoo.comABCL Mar 2024 5.000 callFebruary 23, 2024 | msn.comBenchmark Upgrades AbCellera Biologics (ABCL)February 22, 2024 | benzinga.comAbCellera Biologics Stock (NASDAQ:ABCL) Earnings Dates and Earning CallsFebruary 22, 2024 | businesswire.comAbCellera to Present at Upcoming Investor Conferences in MarchFebruary 22, 2024 | msn.comObesity drugs to expand U.S. GDP by 1% in the coming years: Goldman SachsFebruary 22, 2024 | benzinga.comAbCellera Biologics Stock (NASDAQ:ABCL) Insider TradesFebruary 22, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)February 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)February 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)February 21, 2024 | finance.yahoo.comQ4 2023 Abcellera Biologics Inc Earnings CallFebruary 20, 2024 | benzinga.comRecap: AbCellera Biologics Q4 EarningsFebruary 20, 2024 | finance.yahoo.comAbCellera Reports Full Year 2023 Business ResultsFebruary 20, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesFebruary 20, 2024 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic ShiftsSee More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees586Year FoundedN/APrice Target and Rating Average Stock Price Target$15.86 High Stock Price Target$24.00 Low Stock Price Target$6.00 Potential Upside/Downside+253.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-384.99% Pretax Margin-457.67% Return on Equity-12.36% Return on Assets-9.70% Debt Debt-to-Equity RatioN/A Current Ratio7.33 Quick Ratio7.33 Sales & Book Value Annual Sales$38.03 million Price / Sales34.57 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book1.13Miscellaneous Outstanding Shares292,780,000Free Float197,774,000Market Cap$1.31 billion OptionableOptionable Beta0.38 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 54)J.D., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Comp: $644.4kMr. Neil Aubuchon M.B.A. (Age 54)Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Josephine Hellschlienger Ph.D.Manager of Investor RelationsKathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAMannKindNASDAQ:MNKDPacira BioSciencesNASDAQ:PCRXDay One BiopharmaceuticalsNASDAQ:DAWNXencorNASDAQ:XNCRView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 9,000 shares on 3/15/2024Ownership: 0.007%Vanguard Group Inc.Bought 13,112 shares on 3/11/2024Ownership: 0.004%Goldman Sachs Group Inc.Bought 341,945 shares on 3/1/2024Ownership: 0.205%FIL LtdBought 1,875,872 shares on 2/17/2024Ownership: 0.646%GSA Capital Partners LLPBought 204,480 shares on 2/16/2024Ownership: 0.121%View All Insider TransactionsView All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price target for 2024? 7 brokers have issued 1 year price objectives for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $24.00. On average, they predict the company's share price to reach $15.86 in the next twelve months. This suggests a possible upside of 253.2% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2024? AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL shares have decreased by 21.4% and is now trading at $4.49. View the best growth stocks for 2024 here. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ABCL earnings forecast. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The company had revenue of $9.18 million for the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative net margin of 384.99% and a negative trailing twelve-month return on equity of 12.36%. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ). When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (8.29%), Capital World Investors (2.88%), Federated Hermes Inc. (1.07%), FIL Ltd (0.65%), Norges Bank (0.32%) and Intellectus Partners LLC (0.31%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing“Cash Frenzy” to Hit Banks on March 20?Stansberry ResearchDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.